Chelsearecord.com1h
GLP-1 Weight-loss Drugs Should be Made Affordable for all Americans
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
unilad4h
People are just starting to complain about unexpected side-effect known as 'Ozempic butt'
People who have been using Ozempic have been complaining of a bizarre side-effect, which has been nicknamed 'Ozempic butt'. The phenomenon has swept the US and overseas, as people - including ...
Money Morning5h
3 Pharma Stocks Getting Fat Off GLP-1: Here's the Best Buy Now
Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...
Opinion
Buffalo News5hOpinion
Democrats should start with drug prices | Froma Harrop
President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...
Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
Opinion
Democrats Need To Pick and Choose: Start with Drug Prices
Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...
Novo Nordisk's SWOT analysis: stock outlook amid GLP-1 market growth
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
McKnight's Long-Term Care News15h
FDA expands Ozempic to treat kidney disease in people with diabetes
The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...
FDA Approves Ozempic to Treat Kidney Disease
The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...
Hosted on MSN23h
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...